David M Hilbert

USPTO Granted Patents = 25 (Patent Applications = 12)

CIPO Patents = 6 (Patent Applications = 1)

EPO Patents = 9 (Patent Applications = 9)

Average Co-Inventor Count = 2.7

ph-index = 9

Forward Citations = 340(Granted Patents)

Location History:

Bethesda, MD (US) (1999 - 2020)
Gaithersburg, MD (US) (2022)
Germantown, MD (US) (2020 - 2023)

Company Filing History:

Human Genome Sciences, Inc.

Galactica Pharmaceuticals, Inc.

Aeres Biomedical, Ltd.

patents

8. 1 out of 1,579

Washington University

where one patent can have more than one assignee

Years Active: 1999-2025

Loading Chart...

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12421291 - D-domain containing polypeptides and uses thereof (2025-09-23),

2. 12358995 - De novo binding domain containing polypeptides and uses thereof (2025-07-15),

3. 11730763 - Multifunctional immune cell therapies (2023-08-22),

4. 11464803 - D-domain containing polypeptides and uses thereof (2022-10-11),

5. 11377482 - D-domain containing polypeptides and uses thereof (2022-07-05),

6. 11318165 - D-domain containing polypeptides and uses thereof (2022-05-03),

7. 11008397 - De novo binding domain containing polypeptides and uses thereof (2021-05-18),

8. 10662248 - De novo binding domain containing polypeptides and uses thereof (2020-05-26),

9. 10647775 - De novo binding domain containing polypeptides and uses thereof (2020-05-12),

10. 10526381 - Multivalent and monovalent multispecific complexes and their uses (2020-01-07),

11. 10150800 - EGFR-binding modular recognition domains (2018-12-11),

12. 10087222 - Polynucleotides encoding angiopoietin-2 (ang-2) binding polypeptides (2018-10-02),

13. 9676833 - Ang-2-binding modular recognition domain complexes and pharmaceutical compositions thereof (2017-06-13),

14. 9399668 - Nucleic acids encoding rage fusion proteins (2016-07-26),

15. 9187548 - Antibodies that immunospecifically bind to B lymphocyte stimulator protein (2015-11-17),

Title: David M. Hilbert: Innovator in Immune Cell Therapies

Introduction: David M. Hilbert, located in Bethesda, MD, is a prominent inventor with a remarkable portfolio of 23 patents. His work primarily focuses on cutting-edge immune cell therapies that have significant implications for treating various hyperproliferative disorders, including cancer.

Latest Patents: Among his latest innovations, Hilbert has developed multifunctional chimeric antigen receptor (CAR)-based compositions designed to direct immune responses towards target cells. These compositions aim to treat hyperproliferative disorders such as cancer by using a CAR cell in combination with an Adapter that modulates the immune response both in vitro and in vivo. Another notable patent involves D-domain containing polypeptides (DDpp) that specifically bind to various targets, including BCMA, CD123, CS1, HER2, AFP, and AFP p26. These innovations include methods for producing DDpp fusion proteins, along with their applications in diagnostics and therapeutics.

Career Highlights: David M. Hilbert has significantly impacted the biotech industry through his career at leading companies such as Human Genome Sciences, Inc. and Arcellx, Inc. His expertise and contributions have played a crucial role in advancing research and development in immune cell therapies.

Collaborations: Throughout his career, Hilbert has collaborated with distinguished professionals in the field, including David William Lafleur and Steven M. Ruben. These collaborations have further enhanced the depth and breadth of his innovative contributions.

Conclusion: David M. Hilbert stands out as a leading inventor whose advancements in immune cell therapies mark a promising direction in the fight against diseases like cancer. With his continued research and innovation, he is poised to make lasting impacts in the field of biotechnology and medicine.

This text is generated by artificial intelligence and may not be accurate.